Company intelligence / Profile preview

IRE ELiT

Fleurus, Wallonia, Belgium

Ownership: Private
Employees: ~40
Development stage: Other

Overview

IRE ELiT is a leading global supplier of gallium-68 and germanium-68 generators, now approved as drugs in Europe and APIs in the US, and distributes specialty radiopharmaceuticals including for prostate cancer imaging (via partnership); parent IRE is a world leader in molybdenum-99 and iodine-131 production for established diagnostic and therapeutic use

Therapeutic areas: OncologyOther
Modalities: RadiopharmaceuticalSmall molecule (radiolabeled)
Industry: Biotech

Drug pipeline

2 assets

Galli Ad

Unknown

1 more asset in the full pipeline.

Request access →

Partnerships

Telix Pharmaceuticals (exclusive distribution of TLX591-CDx in France & overseas French territories)Grand Pharmaceutical (distribution partnership in China for gallium-68 generator product)

Beyond the preview

Go deeper on IRE ELiT.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IRE ELiT.

Explore the full profile